Emilia Hardak1,2, Irit Avivi3,4, Lina Berkun5, Ayelet Raz-Pasteur6,7,4, Noa Lavi8,4, Yuval Geffen9, Mordechai Yigla10,4, Ilana Oren6,4. 1. Division of Pulmonary Medicine, Rambam Health Care Campus, 8 Ha'Aliya Street, 31096, Haifa, Israel. e_hardak@rambam.health.gov.il. 2. Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. e_hardak@rambam.health.gov.il. 3. Department of Hematology and Bone Marrow Transplantation, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. 4. Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. 5. Department of Pediatrics, Rambam Health Care Campus, Haifa, Israel. 6. Unit of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel. 7. Department of Internal Medicine A, Rambam Health Care Campus, Haifa, Israel. 8. Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel. 9. Clinical Microbiology Laboratory, Rambam Health Care Campus, Haifa, Israel. 10. Division of Pulmonary Medicine, Rambam Health Care Campus, 8 Ha'Aliya Street, 31096, Haifa, Israel.
Abstract
PURPOSE: The frequency and clinical significance of polymicrobial pneumonia in patients with hematological malignancies (HM) are poorly understood. The aim of the present study is to describe the prevalence, risk factors, clinical characteristics, and outcome of patients with HM and polymicrobial pneumonia. METHODS: Over a 5 year period, 436 consecutive adult patients with HM and pulmonary infiltrates underwent diagnostic fiberoptic bronchoscopy with bronchoalveolar lavage. For 219 patients an infectious etiology was diagnosed, of them 45 (20.5 %) had polymicrobial etiology. Risk factors, clinical course and outcome of polymicrobial pulmonary infection in patients with HM were established. RESULTS: 45 patients with HM were identified with polymicrobial pulmonary infection, 39 of them with two pathogens, and 6 with three. The most common co-pathogen identified was Aspergillus sp. (87 %). Allogeneic hematopoietic stem cell transplantation (HSCT) and graft versus host disease (GVHD) were predictors of polymicrobial infection. Compared to patients with monomicrobial pneumonia, patients with polymicrobialpulmonary infection had a more severe clinical course with more dyspnea (69 vs. 49 %, P = 0.016), hemoptysis (16 vs. 7 %, P = 0.065) and more required respiratory support (27 vs. 17 %, P = 0.125). In-hospital mortality was significantly higher in patients with polymicrobial pulmonary infection than in patients with monomicrobial pulmonary infection (49 vs. 19 %, P < 0.001). CONCLUSIONS: Polymicrobial pulmonary infection occurs quite frequently in patients with HM, especially in allogeneic HSCT recipients and in patients with GVHD. The clinical course of polymicrobial pulmonary infection is severe and mortality approaches 50 %. The clinician taking care of these patients should always look for additional copathogens in profoundly immunosuppressed patients with pneumonia.
PURPOSE: The frequency and clinical significance of polymicrobial pneumonia in patients with hematological malignancies (HM) are poorly understood. The aim of the present study is to describe the prevalence, risk factors, clinical characteristics, and outcome of patients with HM and polymicrobial pneumonia. METHODS: Over a 5 year period, 436 consecutive adult patients with HM and pulmonary infiltrates underwent diagnostic fiberoptic bronchoscopy with bronchoalveolar lavage. For 219 patients an infectious etiology was diagnosed, of them 45 (20.5 %) had polymicrobial etiology. Risk factors, clinical course and outcome of polymicrobial pulmonary infection in patients with HM were established. RESULTS: 45 patients with HM were identified with polymicrobial pulmonary infection, 39 of them with two pathogens, and 6 with three. The most common co-pathogen identified was Aspergillus sp. (87 %). Allogeneic hematopoietic stem cell transplantation (HSCT) and graft versus host disease (GVHD) were predictors of polymicrobial infection. Compared to patients with monomicrobial pneumonia, patients with polymicrobialpulmonary infection had a more severe clinical course with more dyspnea (69 vs. 49 %, P = 0.016), hemoptysis (16 vs. 7 %, P = 0.065) and more required respiratory support (27 vs. 17 %, P = 0.125). In-hospital mortality was significantly higher in patients with polymicrobial pulmonary infection than in patients with monomicrobial pulmonary infection (49 vs. 19 %, P < 0.001). CONCLUSIONS:Polymicrobial pulmonary infection occurs quite frequently in patients with HM, especially in allogeneic HSCT recipients and in patients with GVHD. The clinical course of polymicrobial pulmonary infection is severe and mortality approaches 50 %. The clinician taking care of these patients should always look for additional copathogens in profoundly immunosuppressed patients with pneumonia.
Authors: Georgios Chamilos; Mario Luna; Russell E Lewis; Gerald P Bodey; Roy Chemaly; Jeffrey J Tarrand; Amar Safdar; Issam I Raad; Dimitrios P Kontoyiannis Journal: Haematologica Date: 2006-06-01 Impact factor: 9.941
Authors: Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett Journal: Clin Infect Dis Date: 2008-06-15 Impact factor: 9.079
Authors: D Neofytos; D Horn; E Anaissie; W Steinbach; A Olyaei; J Fishman; M Pfaller; C Chang; K Webster; K Marr Journal: Clin Infect Dis Date: 2009-02-01 Impact factor: 9.079
Authors: P Zak; E Vejrazkova; A Zavrelova; L Pliskova; L Ryskova; P Hubacek; V Stepanova; M Kostal; V Koblizek; P Paterova; Jakub Radocha Journal: Folia Microbiol (Praha) Date: 2019-05-09 Impact factor: 2.099
Authors: Daniel J Lachant; Daniel P Croft; Heather McGrane Minton; Paritosh Prasad; Robert M Kottmann Journal: Respirology Date: 2017-04-05 Impact factor: 6.424
Authors: Ajay Sheshadri; Dimpy P Shah; Myrna Godoy; Jeremy J Erasmus; Juhee Song; Liang Li; Scott E Evans; Roy F Chemaly; Burton F Dickey; David E Ost Journal: PLoS One Date: 2018-05-17 Impact factor: 3.240
Authors: Cristina Gamila Wakfie-Corieh; Alba María Blanes García; Federico Ferrando-Castagnetto; Raquel Valhondo-Rama; Aida Ortega Candil; Cristina Rodríguez Rey; María Nieves Cabrera Martín; Marta García García-Esquinas; Rosa María Couto Caro; María Pedrera Canal; José Luis Carreras Delgado Journal: Eur J Nucl Med Mol Imaging Date: 2020-09-08 Impact factor: 10.057